Champions Oncology, Inc. (CSBR) Q3 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings. Welcome to the Champions Oncology third quarter fiscal year 2026 earnings call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note this conference is being recorded. I will now turn the conference over to your host, Rob Braynon, CEO at Champions Oncology. You may begin. Good afternoon, and thank you for joining us for our third quarter fiscal 2026 earnings call. I'm Rob Brayman, CEO of Champions Oncology, and I'm joined today by our CFO, David Miller. Before we begin, I'll remind everyone that today's remarks may include forward-looking statements. Actual results may differ materially, and additional information can be found in our filings with the SEC. Before I walk through the quarter, let me briefly highlight three key takeaways. First, we delivered another quarter of strong operational performance, including record services revenue and our third consecutive quarter of positive adjusted EBITDA. Second, while quarterly revenue can fluctuate in our business, we remain on track for full-year revenue growth and full-year positive adjusted EBITDA, while continuing to invest in both our data platform and our discovery therapeutic subsidiary. And third... We're beginning to see early momentum in our data business, including new deals closed during the quarter and additional revenue expected in the fourth quarter. Overall, pleased with the progress we're making as we scale the core services business, promoting the longer-term growth opportunities in data and drug discovery. Turning to the quarter in more detail, we delivered another quarter of record services re...